[1] |
Beale EG, Harvey BJ, Forest C. PCK1 and PCK2 as candidate diabetes and obesity genes[J]. Cell Biochem Biophys, 2007, 48(2-3): 89-95.
|
[2] |
Yu S, Meng S, Xiang M, et al. Phosphoenolpyruvate carboxykinase in cell metabolism: roles and mechanisms beyond gluconeogenesis[J]. Mol Metab, 2021, 53: 101257.
|
[3] |
Dunten P, Belunis C, Crowther R, et al. Crystal structure of human cytosolic phosphoenolpyruvate carboxykinase reveals a new GTPbinding site[J]. J Mol Biol, 2002, 316(2): 257-264.
|
[4] |
Latorre-Muro P, Baeza J, Hurtado-Guerrero R, et al. Selfacetylation at the active site of phosphoenolpyruvate carboxykinase(PCK1) controls enzyme activity[J]. J Biol Chem, 2021, 296:100205.
|
[5] |
Beale EG, Hammer RE, Antoine B, et al. Disregulated glyceroneogenesis: PCK1 as a candidate diabetes and obesity gene[J]. Trends Endocrinol Metab, 2004, 15(3): 129-135.
|
[6] |
Shi L, An S, Liu Y, et al. PCK1 regulates glycolysis and tumor progression in clear cell renal cell carcinoma through LDHA[J].Onco Targets Ther, 2020, 13: 2613-2627.
|
[7] |
Bi Y, Yin B, Fan G. Identification of metabolism genes related to hepatocarcinogenesis and progression in type 2 diabetes mellitus via co-expression networks analysis[J]. Hereditas, 2021, 158(1):14.
|
[8] |
Tang Y, Zhang Y, Wang C, et al. Overexpression of PCK1 gene antagonizes hepatocellular carcinoma through the activation of gluconeogenesis and suppression of glycolysis pathways[J]. Cell Physiol Biochem, 2018, 47(1): 344-355.
|
[9] |
Zhang X, Tao G, Jiang J, et al. PCK1 activates oncogenic autophagy via down-regulation serine phosphorylation of UBAP2L and antagonizes colorectal cancer growth[J]. Cancer Cell Int, 2023,23(1): 68.
|
[10] |
Montal ED, Dewi R, Bhalla K, et al. PEPCK coordinates the regulation of central carbon metabolism to promote cancer cell growth[J]. Mol Cell, 2015, 60(4): 571-583.
|
[11] |
Zhu XR, Peng SQ, Wang L, et al. Identification of phosphoenolpyruvate carboxykinase 1 as a potential therapeutic target for pancreatic cancer[J]. Cell Death Dis, 2021, 12(10): 918.
|
[12] |
蒙秀东, 李昕, 袁旭, 等.胃癌前病变相关关键基因的生物信息学分析[J/OL]. 消化肿瘤杂志(电子版), 2021, 13(4): 274-281.
|
[13] |
沈昕草, 朱孝仁, 刘媛媛, 等. 磷酸烯醇式丙酮酸羧激酶1 对胃癌细胞生物学行为的影响及相关机制[J]. 江苏大学学报(医学版), 2023, 33(1): 9-16.
|
[14] |
Li Y, Zhang M, Dorfman RG, et al. SIRT2 promotes the migration and invasion of gastric cancer through RAS/ERK/JNK/MMP-9 pathway by increasing PEPCK1-related metabolism[J]. Neoplasia,2018, 20(7): 745-756.
|
[15] |
Li Y, Luo S, Ma R, et al. Upregulation of cytosolic phosphoenolpyruvate carboxykinase is a critical metabolic event in melanoma cells that repopulate tumors[J]. Cancer Res, 2015, 75(7):1191-1196.
|
[16] |
Tang K, Zhu L, Chen J, et al. Hypoxia promotes breast cancer cell growth by activating a glycogen metabolic program[J]. Cancer Res,2021, 81(19): 4949-4963.
|
[17] |
Wen YC, Liu CL, Yeh HL, et al. PCK1 regulates neuroendocrine differentiation in a positive feedback loop of LIF/ZBTB46 signalling in castration-resistant prostate cancer[J]. Br J Cancer,2022, 126(5): 778-790.
|
[18] |
Tuo L, Xiang J, Pan X, et al. PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27(Kip1) axis[J]. J Exp Clin Cancer Res, 2019, 38(1): 50.
|
[19] |
Tuo L, Xiang J, Pan X, et al. PCK1 downregulation promotes TXNRD1 expression and hepatoma cell growth via the Nrf2/Keap1 pathway[J]. Front Oncol, 2018, 8: 611.
|
[20] |
Liu R, Gou D, Xiang J, et al. O-GlcNAc modified-TIP60/KAT5 is required for PCK1 deficiency-induced HCC metastasis[J].Oncogene, 2021, 40(50): 6707-6719.
|
[21] |
Jin L, Alesi GN, Kang S. Glutaminolysis as a target for cancer therapy[J]. Oncogene, 2016, 35(28): 3619-3625.
|
[22] |
Wang Z, Dong C. Gluconeogenesis in cancer: function and regulation of PEPCK, FBPase, and G6Pase[J]. Trends Cancer,2019, 5(1): 30-45.
|
[23] |
Ma R, Ji T, Zhang H, et al. A PCK1-directed glycogen metabolic program regulates formation and maintenance of memory CD8(+) T cells[J]. Nat Cell Biol, 2018, 20(1): 21-27.
|
[24] |
Liu MX, Jin L, Sun SJ, et al. Metabolic reprogramming by PCK1 promotes TCA cataplerosis, oxidative stress and apoptosis in liver cancer cells and suppresses hepatocellular carcinoma[J].Oncogene, 2018, 37(12): 1637-1653.
|
[25] |
Xu D, Wang Z, Xia Y, et al. The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis[J]. Nature, 2020,580(7804): 530-535.
|
[26] |
Shao F, Bian X, Jiang H, et al. Association of phosphoenolpyruvate carboxykinase 1 protein kinase activity-dependent sterol regulatory element-binding protein 1 activation with prognosis of oesophageal carcinoma[J]. Eur J Cancer, 2021, 142: 123-131.
|
[27] |
Gou D, Liu R, Shan X, et al. Gluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression[J]. J Clin Invest, 2023, 133(13): e161713.
|
[28] |
Yamaguchi N, Weinberg EM, Nguyen A, et al. PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis[J]. Elife, 2019, 8:e52135.
|
[29] |
Jing Z, Gao J, Li J, et al. Acetylation-induced PCK isoenzyme transition promotes metabolic adaption of liver cancer to systemic therapy[J]. Cancer Lett, 2021, 519: 46-62.
|
[30] |
Misbah M, Kumar M, Lee KH, et al. Identification of novel miRNAs, targeting genes, signaling pathway, and the small molecule for overcoming oxaliplatin resistance of metastatic colorectal cancer[J]. Biomed Res Int, 2022: 3825760.
|
[31] |
Ren M, Wang L, Gao ZX, et al. Overcoming chemoresistance to braf inhibitor in melanoma via targeted inhibition of phosphoenolpyruvate carboxykinase1 using 3-mercaptopropionic acid[J]. Bioengineered, 2022, 13(5): 13571-13586.
|